Stryker Corporation $SYK Shares Sold by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. decreased its position in Stryker Corporation (NYSE:SYK) by 6.2% in the 1st quarter, HoldingsChannel reports. The firm owned 1,658 shares of the medical technology company’s stock after selling 110 shares during the period. Tocqueville Asset Management L.P.’s holdings in Stryker were worth $617,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Capital A Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Goodman Advisory Group LLC purchased a new position in shares of Stryker during the 1st quarter worth $32,000. City Holding Co. lifted its stake in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the period. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the first quarter worth $40,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Stryker in the fourth quarter valued at $42,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of NYSE:SYK opened at $381.91 on Tuesday. The business’s 50-day simple moving average is $386.77 and its 200 day simple moving average is $379.38. The company has a market cap of $146.01 billion, a P/E ratio of 50.58, a PEG ratio of 2.78 and a beta of 0.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.81 earnings per share. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have issued reports on SYK shares. Needham & Company LLC raised their price target on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Roth Mkm boosted their target price on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Evercore ISI lifted their price target on shares of Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.